Kestra Investment Management LLC Acquires Shares of 1,708 United Therapeutics Co. (NASDAQ:UTHR)

Kestra Investment Management LLC acquired a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,708 shares of the biotechnology company’s stock, valued at approximately $603,000.

A number of other institutional investors and hedge funds have also bought and sold shares of UTHR. World Investment Advisors LLC purchased a new stake in shares of United Therapeutics during the 3rd quarter valued at about $139,206,000. FMR LLC boosted its holdings in shares of United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after acquiring an additional 314,004 shares during the last quarter. AustralianSuper Pty Ltd boosted its holdings in shares of United Therapeutics by 577.1% during the 4th quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock valued at $66,962,000 after acquiring an additional 161,751 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after acquiring an additional 152,249 shares during the last quarter. Finally, Franklin Resources Inc. boosted its holdings in shares of United Therapeutics by 97.7% during the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after acquiring an additional 123,929 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on UTHR shares. The Goldman Sachs Group raised their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. UBS Group raised their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. Argus raised their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, LADENBURG THALM/SH SH raised their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $382.08.

United Therapeutics Trading Up 0.6 %

NASDAQ UTHR opened at $372.83 on Wednesday. United Therapeutics Co. has a 12 month low of $213.75 and a 12 month high of $417.82. The stock has a market cap of $16.65 billion, a price-to-earnings ratio of 16.37, a PEG ratio of 0.96 and a beta of 0.57. The company’s 50 day moving average is $362.21 and its two-hundred day moving average is $359.74.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the sale, the executive vice president now owns 36,710 shares in the company, valued at $13,743,122.70. This trade represents a 17.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $896,950.62. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 121,864 shares of company stock worth $44,516,965. Company insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.